Literature DB >> 11012330

Improvement of Huntington's disease with olanzapine and valproate.

V E Grove, J Quintanilla, G T DeVaney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11012330     DOI： 10.1056/NEJM200009283431316

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  27 in total

1.  Quetiapine in Huntington's disease: a first case report.

Authors:  Raphael M Bonelli; Gerald Niederwieser
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

Review 2.  Chorea and related disorders.

Authors:  R Bhidayasiri; D D Truong
Journal:  Postgrad Med J       Date:  2004-09       Impact factor: 2.401

3.  Treatment of huntington disease.

Authors:  Aleksandar Videnovic
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 4.  An overview of psychiatric symptoms in Huntington's disease.

Authors:  K E Anderson; K S Marder
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

5.  Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.

Authors:  Georg Karpel-Massler; Richard Eric Kast; Mike-Andrew Westhoff; Annika Dwucet; Nathalie Welscher; Lisa Nonnenmacher; Michal Hlavac; Markus David Siegelin; Christian Rainer Wirtz; Klaus-Michael Debatin; Marc-Eric Halatsch
Journal:  J Neurooncol       Date:  2014-12-19       Impact factor: 4.130

6.  Psychosis Due to Neurologic Conditions.

Authors:  David B. Arciniegas; Jeannie L. Topkoff; Kerri Held; Lauren Frey
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

Review 7.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 8.  An Update on the Treatment of Chorea.

Authors:  Erin Feinstein; Ruth Walker
Journal:  Curr Treat Options Neurol       Date:  2018-09-25       Impact factor: 3.598

Review 9.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 10.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.